Bellevue — Bellevue, Washington

Bellevue is a clinical research site located in Bellevue, Washington, United States 98004.

Crixeo Clinical Trials Trust Score: 11/100 (FAILING). This profile has not yet been claimed by the site owner.

Bellevue has participated in 2 clinical trials with 1 currently active.

Therapeutic areas: Diabetic Macular Edema (DME), Contraception.

Sponsors: EyeBiotech Ltd., Sumitomo Pharma Switzerland GmbH.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Bellevue

Browse all research sites in Washington · View every site in Bellevue

• Overlake Cancer Center at Overlake Hospital Medical Center
• Overtake Hospital Medical Center
• Overlake Hospital
• Overlake Cancer Center at Overtake Hospital Medical Center
• University of Washington Medical Center
• Overlake Hospital Medical Center
• Northwest Clinical Research Center
• Overlake Medical Center
• Research Site
• Swedish Cancer Institute-Eastside Oncology Hematology
• FHCC Overlake
• Pacific Northwest Retina

Sponsor Feasibility Report

Trust Score: 11/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Bellevue?

Bellevue has a Crixeo Trust Score of 11/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Bellevue conducted?

Bellevue has 2 clinical trials on record, with 1 currently active. Their work covers Diabetic Macular Edema (DME), Contraception.

Is Bellevue accredited by Crixeo Clinical Trials?

Bellevue has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Bellevue?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.